Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

Wei Wu(Sun Yat-sen University), Jieqiong Liu(Sun Yat-sen University), Yan Nie(Sun Yat-sen University), Jiewen Chen(Center for Excellence in Molecular Cell Science), Yandan Yao(Sun Yat-sen University), Zhanghai He(Sun Yat-sen University), Fengxi Su(Sun Yat-sen University), Liang Jin(Kunming Medical University), Nanyan Rao(Sun Yat-sen University), Heran Deng(Sun Yat-sen University), Yaping Yang(Sun Yat-sen University)
BMC Cancer
July 27, 2021
Cited by 14


Related Papers